0001415889-24-018440.txt : 20240628
0001415889-24-018440.hdr.sgml : 20240628
20240628163043
ACCESSION NUMBER: 0001415889-24-018440
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240626
FILED AS OF DATE: 20240628
DATE AS OF CHANGE: 20240628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gujrathi Sheila
CENTRAL INDEX KEY: 0001575202
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40475
FILM NUMBER: 241086189
MAIL ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Janux Therapeutics, Inc.
CENTRAL INDEX KEY: 0001817713
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 822289112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10955 VISTA SORRENTO PARKWAY
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 751-4493
MAIL ADDRESS:
STREET 1: 10955 VISTA SORRENTO PARKWAY
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-06282024_040639.xml
X0508
4
2024-06-26
0001817713
Janux Therapeutics, Inc.
JANX
0001575202
Gujrathi Sheila
C/O JANUX THERAPEUTICS, INC.
10955 VISTA SORRENTO PARKWAY, SUITE 200
SAN DIEGO
CA
92130
true
false
false
false
0
Common Stock
2024-06-26
4
A
0
2500
0
A
110528
D
Stock Option (right to buy)
39.80
2024-06-26
4
A
0
8350
0
A
2034-06-25
Common Stock
8350
8350
D
Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
/s/ Maria Dobek, Attorney-in-Fact
2024-06-27